Paul L?vesque, CEO, acquired 40,000 Common Shares on a direct ownership basis at a price of US$2.530 through a prospectus or prospectus exempt offering on January 19th, 2021. The insider also acquired 20,000 Warrants with an exercise price of US$3.180 until January 19, 2024. This represents a $128,878 investment into the company's shares and an account share holdings change of 56.2%.
Paul Pommier, a Director, acquired 30,000 Common Shares and 15,000 Warrants on a direct ownership basis. This represents a $96,659 investment into the company's shares and an account share holdings change of 7.7%.
Theratechnologies is in the Pharmaceuticals Sub Industry Group under the Healthcare Sector.
Theratechnologies Inc is a Canada-based specialty pharmaceutical company. The Company addresses medical needs to promote healthy living for human immunodeficiency virus (HIV) patients. Its products include EGRIFTA and Ibalizumab. EGRIFTA (tesamorelin for injection) refers to tesamorelin and it is indicated for the reduction of excess abdominal fat in HIV infected patients with lipodystrophy. EGRIFTA is indicated for the treatment of excess visceral adipose tissue (VAT), as assessed by waist circumference of approximately 100 centimeters for males and approximately 90 centimeters for females. Ibalizumab is a cluster difference 4 (CD4)-directed HIV entryinhibitor, which focuses on treating multidrug resistant HIV-1 infection (MDR HIV-1). Ibalizumab binds to the second extracellular domain of the CD4 receptor. Ibalizumab has completed the Phase III trial. EGRIFTA is available in Canada and in the United States. The Company distributes EGRIFTA in the United States through RxC Acquisition.
No Comments